Evidence map›Paper›PMID 36807761›Full record

ArticleJournal of cancer research and clinical oncology2023

Discovery of potential biomarkers for lung cancer classification based on human proteome microarrays using Stochastic Gradient Boosting approach.

Ning Yao, Jianbo Pan, Xicheng Chen, Pengpeng Li, Yang Li, Zhenyan Wang, Tianhua Yao, Li Qian, Dong Yi, Yazhou Wu

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Ning Yao *Department of Health Statistics, College of Preventive Medicine, Army Medical University, No.30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Jianbo Pan *Center for Novel Target and Therapeutic Intervention, Institute of Life Sciences, Chongqing Medical University, Chongqing, 400016, China.
Xicheng ChenDepartment of Health Statistics, College of Preventive Medicine, Army Medical University, No.30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Pengpeng LiDepartment of Health Statistics, College of Preventive Medicine, Army Medical University, No.30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Yang LiDepartment of Health Statistics, College of Preventive Medicine, Army Medical University, No.30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Zhenyan WangDepartment of Health Statistics, College of Preventive Medicine, Army Medical University, No.30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Tianhua YaoDepartment of Health Statistics, College of Preventive Medicine, Army Medical University, No.30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Li QianDepartment of Health Statistics, College of Preventive Medicine, Army Medical University, No.30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China.
Dong YiDepartment of Health Statistics, College of Preventive Medicine, Army Medical University, No.30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China. yd_house@hotmail.com.
Yazhou WuDepartment of Health Statistics, College of Preventive Medicine, Army Medical University, No.30 Gaotanyan Street, Shapingba District, Chongqing, 400038, China. asiawu@tmmu.edu.cn.
Army Medical University · CNChongqing Medical University · CN

Funding

National Natural Science Foundation of China 82173621
6 · The paper itself

Abstract

purposeEarly identification of lung cancer (LC) will considerably facilitate the intervention and prevention of LC. The human proteome micro-arrays approach can be used as a "liquid biopsy" to diagnose LC to complement conventional diagnosis, which needs advanced bioinformatics methods such as feature selection (FS) and refined machine learning models.

methodsA two-stage FS methodology by infusing Pearson's Correlation (PC) with a univariate filter (SBF) or recursive feature elimination (RFE) was used to reduce the redundancy of the original dataset. The Stochastic Gradient Boosting (SGB), Random Forest (RF), and Support Vector Machine (SVM) techniques were applied to build ensemble classifiers based on four subsets. The synthetic minority oversampling technique (SMOTE) was used in the preprocessing of imbalanced data.

resultsFS approach with SBF and RFE extracted 25 and 55 features, respectively, with 14 overlapped ones. All three ensemble models demonstrate superior accuracy (ranging from 0.867 to 0.967) and sensitivity (0.917 to 1.00) in the test datasets with SGB of SBF subset outperforming others. The SMOTE technique has improved the model performance in the training process. Three of the top selected candidate biomarkers (LGR4, CDC34, and GHRHR) were highly suggested to play a role in lung tumorigenesis.

conclusionA novel hybrid FS method with classical ensemble machine learning algorithms was first used in the classification of protein microarray data. The parsimony model constructed by the SGB algorithm with the appropriate FS and SMOTE approach performs well in the classification task with higher sensitivity and specificity. Standardization and innovation of bioinformatics approach for protein microarray analysis need further exploration and validation.

Indexed as

Lung NeoplasmsProteomeAlgorithmsBiomarkersHumansLungBiomarkersProteomeBiomarkersClassificationEnsemble learningLung cancerProteome microarrays

Identifiers

PMID36807761
PMCPMC11797712
OpenAlexW4321349483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.